| Ticker Symbol: | PANC |
|---|---|
| Exchange: | NASD |
| Contact Info: | 134 Coolidge Avenue Watertown MA 02472 617-926-1551 |
| CEO/President: | Alan W. Dunton M.D |
| Industry: | Medical - Biomedical / Standard Industry Code: 2836 |
| Description: | Panacos is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos\' proprietary discovery technologies and lead therapeutic candidate PA-457 focus on novel targets in the virus life cycle, including virus fusion and virus maturation. |
| Shares Outstanding: | 53,640 (000) | Market Value: | 10,460 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 44.80% | Number of Inst.Shareholders: | 6.90% |
| Last Quarter Sales: | 0.02 ($Mil.) | Last Quarter Net Income: | -8.15 ($Mil.) |
| Last Quarter EPS: | -0.15 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.66 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |